Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.

Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S; Bixalomer Study Group.

Ther Apher Dial. 2014 Apr;18(2):122-31. doi: 10.1111/1744-9987.12068. Epub 2013 Aug 27.

PMID:
24720402
[PubMed - indexed for MEDLINE]
2.

Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.

Akizawa T, Kameoka C, Kaneko Y, Kawasaki S; Bixalomer Study Group.

Ther Apher Dial. 2013 Dec;17(6):612-9. doi: 10.1111/1744-9987.12023. Epub 2013 Mar 11.

PMID:
24330556
[PubMed - indexed for MEDLINE]
3.

Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.

Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.

Ther Apher Dial. 2014 Jun;18 Suppl 2:24-32. doi: 10.1111/1744-9987.12202.

PMID:
24975892
[PubMed - indexed for MEDLINE]
4.

A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.

Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H.

Nephrol Dial Transplant. 2014 May;29(5):1053-60. doi: 10.1093/ndt/gft483. Epub 2013 Dec 26.

PMID:
24376274
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.

Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M.

Nephrology (Carlton). 2011 Nov;16(8):743-50. doi: 10.1111/j.1440-1797.2011.01509.x.

PMID:
21854503
[PubMed - indexed for MEDLINE]
6.

Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.

Hatakeyama S, Murasawa H, Narita T, Oikawa M, Fujita N, Iwamura H, Mikami J, Kojima Y, Sato T, Fukushi K, Ishibashi Y, Hashimoto Y, Koie T, Saitoh H, Funyu T, Ohyama C.

BMC Nephrol. 2013 Oct 12;14:222. doi: 10.1186/1471-2369-14-222.

PMID:
24119202
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.

Perit Dial Int. 2007 Nov-Dec;27(6):697-701.

PMID:
17984434
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

PMID:
18820280
[PubMed - indexed for MEDLINE]
Free Article
9.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
[PubMed - indexed for MEDLINE]
10.

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.

Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.

PMID:
22982903
[PubMed - indexed for MEDLINE]
Free Article
11.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

PMID:
24821148
[PubMed - indexed for MEDLINE]
Free Article
12.

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; Alberta Kidney Disease Network.

Nephrol Dial Transplant. 2007 Oct;22(10):2856-66. Review.

PMID:
17906326
[PubMed - indexed for MEDLINE]
Free Article
13.

Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.

Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T; Research Group for Future Hemodialysis.

Ther Apher Dial. 2008 Apr;12(2):126-32. doi: 10.1111/j.1744-9987.2008.00557.x.

PMID:
18387160
[PubMed - indexed for MEDLINE]
14.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pai AB, Shepler BM.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Review.

PMID:
19397463
[PubMed - indexed for MEDLINE]
15.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107. Epub 2008 May 1.

PMID:
18450923
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

Kasai S, Sato K, Murata Y, Kinoshita Y.

Ther Apher Dial. 2012 Aug;16(4):341-9. doi: 10.1111/j.1744-9987.2012.01071.x. Epub 2012 May 11.

PMID:
22817122
[PubMed - indexed for MEDLINE]
17.
18.

Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?

Senatore M, Coppolino G, Papalia T, Greco R, Lofaro D, Bonofiglio R.

Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1352-4. No abstract available.

PMID:
22195373
[PubMed - indexed for MEDLINE]
19.

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.

Drugs. 2008;68(1):85-104. Review.

PMID:
18081374
[PubMed - indexed for MEDLINE]
20.

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.

Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.

Ren Fail. 2006;28(8):701-7.

PMID:
17162430
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk